Efficacy of intravenous immunoglobulin treatment in refractory uveitis

Ocular Immunology and Inflammation

Volumn 14, Issue 6, 2006, Pages 367-374

  Onal, Sumru ^a,b   Foster, C Stephen ^a   Ahmed, A Razzaque ^c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b MARMARA UNIVERSITY   (Turkey)

^c NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Intravenous immunoglobulin; Refractory; Uveitis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BEVACIZUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PREDNISONE; STEROID; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; CATARACT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; HAIR LOSS; HUMAN; HYPOGLYCEMIA; LEUKOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; RELAPSE; RETINA MACULA EDEMA; REVIEW; SECONDARY GLAUCOMA; SINGLE DRUG DOSE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; UVEITIS, ANTERIOR; VISUAL ACUITY;

EID: 33845651180     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940601025966     Document Type: Review

References (24)

1. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464-468.
2. Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum. 1992;35:1126-1133.
3. Achiron A, Barek Y, Goren M, et al. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol. 1996;104(suppl. 1):67-70.
4. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol. 1994;12:163-168.
5. Cosi V, Lombardi M, Piccolo G, Erbetla A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand. 1991;84:81-84.
6. Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immunoglobulin. Clin Exp Immunol. 1994;97(suppl. 1):31-38.
7. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol. 2005;6:327-342.
8. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. A preliminary study. Ophthalmology. 1999;106:2136-2143.
9. Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed RA. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology. 2004;111:1380-1382.
10. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303-308.
11. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491-500.
12. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
13. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intrvenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17:1144-1148.
14. Dwyer JM. Manipulating the immune system with immunoglobulin. N Engl J Med. 1992;326:107-116.
15. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, Kazatchkine MD. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol. 1996;10(suppl. 1):3-9.
16. Frohman LP, Cook SD, Bielory L. Dysgammaglobulinemia in steroid-dependent optic neuritis: response to gammaglobulin treatment. J Clin Neuroophthalmol. 1991;11:241-245.
17. Blum M, Andrassy K, Adler D, et al. Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 1997;235:599-602.
18. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol. 1999;127:545-549.
19. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behçet's disease. Br J Ophthalmol. 2001;85:1287-1288.
20. Le Hoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2000;8.49-57.
21. Cassoux N, Karmochkine M, Bodaghi B, et al. Intravenous immunoglobulins efficacy in the treatment of birdshot retinochoroiditis [abstract]. Invest Ophthalmol Vis Sci. 2000; 41(suppl.):S782.
22. Obrador E, Peinado E, de Kozak Y, Ruiz-Moreno JM, Alio JL. Human immunoglobulin preparations for intravenous use prevent endotoxin-induced uveitis in rats. Ophthalmic Res. 1999;31:59-67.
23. Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, Druet P, Bellon B. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol. 1993;5:1559-1567.
24. Becker MD, Rosenbaum JT. Current and future trends in the use of immunosuppressive agents in patients with uveitis. Curr Opin Ophthalmol. 2000;11:472-477.